Computer Vision AI and Precision Genomic Collaboration Aims to Increase Early Detection Rates, Improving Survival Chances for Millions DENVER , Aug. 27, 2024 /PRNewswire/ -- Imidex, a leading medical device company specializing in utilizing AI for lung nodule and mass detection, and Orbit Genomics, a pioneer in DNA sequencing for precision cancer diagnosis, today announced a strategic relationship aimed at helping to reduce the number of lives lost to lung cancer. Lung cancer is currently the leading cause of cancer-related deaths around the world.
"Imidex's technology is one of the only FDA 510(k) cleared devices capable of screening broad populations and incidentally detecting lung nodules and masses from chest x-rays. This positions us as the front-end solution to identify high-risk populations for further evaluation at the lowest cost," said Wes Bolsen , CEO of Imidex. "By leveraging chest x-ray, we have the ability to opportunistically identify millions more patients with pulmonary nodules that are unwilling or not qualified to get a low dose radiation CT scan.
" Low-dose computed tomography (CT) is currently the standard method for lung cancer screening in high-risk patients in the United States . However, less than 6% of high-risk patients in the U.S.
undergo this screening, with some states reporting rates as low as 1%. Chest x-ray (CXR) offers a broader reach for the screening and incidental detection of lung nodules, which are often early indicators of lung cancer. I.